Shares of Definitive Healthcare Corp. (NASDAQ:DH – Get Free Report) hit a new 52-week low on Wednesday after Canaccord Genuity Group lowered their price target on the stock from $10.00 to $8.00. Canaccord Genuity Group currently has a hold rating on the stock. Definitive Healthcare traded as low as $4.38 and last traded at $4.89, with a volume of 1416771 shares trading hands. The stock had previously closed at $7.25.
DH has been the subject of a number of other research reports. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a report on Wednesday. Stifel Nicolaus decreased their price objective on Definitive Healthcare from $11.00 to $9.50 and set a “buy” rating for the company in a report on Wednesday. Barclays increased their price objective on Definitive Healthcare from $10.00 to $11.00 and gave the stock an “equal weight” rating in a report on Friday, March 1st. Finally, Morgan Stanley cut Definitive Healthcare from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $11.50 to $9.00 in a research note on Wednesday. Eight analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $10.81.
Institutional Investors Weigh In On Definitive Healthcare
Several institutional investors have recently modified their holdings of the business. Arizona State Retirement System boosted its position in shares of Definitive Healthcare by 13.6% during the fourth quarter. Arizona State Retirement System now owns 14,253 shares of the company’s stock valued at $142,000 after buying an additional 1,701 shares during the last quarter. OLD National Bancorp IN boosted its position in Definitive Healthcare by 14.5% in the third quarter. OLD National Bancorp IN now owns 20,613 shares of the company’s stock worth $165,000 after purchasing an additional 2,609 shares during the last quarter. Corton Capital Inc. boosted its position in Definitive Healthcare by 17.0% in the third quarter. Corton Capital Inc. now owns 19,964 shares of the company’s stock worth $160,000 after purchasing an additional 2,898 shares during the last quarter. Swiss National Bank boosted its position in Definitive Healthcare by 2.9% in the first quarter. Swiss National Bank now owns 103,300 shares of the company’s stock worth $834,000 after purchasing an additional 2,900 shares during the last quarter. Finally, Wrapmanager Inc. boosted its position in Definitive Healthcare by 10.8% in the third quarter. Wrapmanager Inc. now owns 36,501 shares of the company’s stock worth $292,000 after purchasing an additional 3,563 shares during the last quarter. 98.67% of the stock is owned by hedge funds and other institutional investors.
Definitive Healthcare Price Performance
The firm has a market capitalization of $630.18 million, a PE ratio of -3.01, a PEG ratio of 6.12 and a beta of 1.41. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.31 and a quick ratio of 2.31. The firm has a 50-day simple moving average of $7.70 and a 200-day simple moving average of $8.29.
Definitive Healthcare (NASDAQ:DH – Get Free Report) last announced its earnings results on Wednesday, February 28th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.02). The firm had revenue of $65.93 million during the quarter, compared to analysts’ expectations of $66.01 million. Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. As a group, equities analysts forecast that Definitive Healthcare Corp. will post 0.11 earnings per share for the current year.
Definitive Healthcare Company Profile
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.